Document Fragment View
Fragment Information
Showing contexts for: reverse engineering in Petitioner vs Union Of India on 30 September, 2020Matching Fragments
6.R&D in Generics refers to ‘Reverse’ Engineering of equivalents of Proprietary Medicines by independent process. Generic Medicines could enter market upon expiry of patent period for a Proprietary Medicine.
7.‘Active Pharmaceutical Ingredients’ (‘APIs’) refers to the ingredients in a medicine that act upon the illness of the patient. These ingredients constitute the nucleus of any medicine and are also referred to as ‘Bulk Drugs’.
Case of the Petitioner in WP.No.9610 of 2016
43.W.P.No.9610 of 2016 is the first Writ Petition filed by Petitioner against the http://www.judis.nic.in W.P.Nos.11777 & 16622 of 2017 co-financing Banks. In W.P.No.9610 of 2016, the contentions of the Petitioner were that it has been promoted by a Research Chemist specializing in reverse engineering of Hi-Tech, High Value, Low Volume life-saving molecules applied in Cancer Treatment. The Petitioner narrated the unique distinctions and relevance that it has accumulated over the years with its in-house R&D capabilities.